Takeuchi T, et al. – The efficacy and safety of sirukumab were examined in patients with active rheumatoid arthritis (RA) refractory to disease–modifying antirheumatic drugs. Results displayed that sirukumab 100 mg every 2 weeks and 50 mg every 4 weeks offered significant reductions in RA symptoms, inhibition of structural damage progression and physical function and quality of life improvements, with an expected safety profile.